While numbers of mice in the pilot study of trametinib in combination with MET inhibitor glesatinib were low, this regimen showed promising increased magnitude and durability of response (average decrease of 91% tumor volume, i.e., 320 mm3 to 29 mm3), compared to trametinib alone (Figure 3). This evidence concerns the gene MET and neoplasm.